読み込み中
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
前日終値
$1.91
+$0.02 · +1.06%
日中の時刻はETです。市場データは遅延する場合があります。
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
日中レンジ
現在 $1.91
52週レンジ
現在 $1.91
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
44
適正価値
センチメント
54
まちまち
リスク
65
高リスク
モメンタム
31
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
日中レンジ
現在 $1.91
52週レンジ
現在 $1.91
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 35.97万 USD | 40.1万 USD | 14.58万 USD | 11.98万 USD | 4.6万 USD |
| 売上原価 | 2.38万 USD | 2.81万 USD | — | — | — |
| 粗利益 | 33.59万 USD | 37.29万 USD | 14.58万 USD | 11.98万 USD | 4.6万 USD |
| 研究開発 | 1009.47万 USD | 534.87万 USD | 403.46万 USD | 351.34万 USD | 72.91万 USD |
| 販売・一般管理 | 588.83万 USD | 657.94万 USD | 1133.2万 USD | 1558.05万 USD | 2562.48万 USD |
| 営業費用 | 1598.3万 USD | 1192.81万 USD | 1536.66万 USD | 1898.33万 USD | 2635.39万 USD |
| 受取利息 | 26.62万 USD | 61.61万 USD | 55.23万 USD | 1.17万 USD | — |
| 支払利息 | — | — | — | — | 181.54万 USD |
| 減価償却費と償却費 | 21万 USD | 18.91万 USD | 16.57万 USD | 12.05万 USD | 8.91万 USD |
| 営業利益 | −1564.71万 USD | −1155.52万 USD | −1522.08万 USD | −1886.35万 USD | −2630.79万 USD |
| 純利益 | −1424.2万 USD | −897.94万 USD | −1041.77万 USD | −1322.23万 USD | −4430.33万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは3件と限定的です
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年9月8日 | 1:20 | — | — |
株式分割 | 2021年10月27日 | 1:4,000 | — | — |
株式分割 | 2015年7月7日 | 1:20 | — | — |
株式分割 | 2013年4月15日 | 1:50 | — | — |
株式分割 | 2008年3月3日 | 1:250 | — | — |
発効済み 2026年9月8日
1:20
発効済み 2021年10月27日
1:4,000
発効済み 2015年7月7日
1:20
発効済み 2013年4月15日
1:50
発効済み 2008年3月3日
1:250
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
